{
    "2019-07-04": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Karyopharm Gets Accelerated FDA Approval for Myeloma Drug",
                "features": {
                    "keywords": [
                        "FDA Approval",
                        "Myeloma Drug",
                        "Accelerated"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Boasting A 25% Return On Equity, Is Johnson & Johnson (NYSE:JNJ) A Top Quality Stock?",
                "features": {
                    "keywords": [
                        "Return On Equity",
                        "Johnson & Johnson",
                        "Quality Stock"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "consumer goods"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}